Literature DB >> 16433470

A rapid HIV testing program for labor and delivery in an inner-city teaching hospital.

Erika Aaron1, Amy B Levine, Keri Monahan, Charles P Biondo.   

Abstract

Although perinatal HIV prophylaxis is probably the most successful HIV prevention intervention to date, between 280 and 370 HIV-positive infants are born in the United States each year. A major reason for continuing vertical transmission is that some HIV-infected women are not aware of their positive HIV serostatus before delivery. A rapid HIV testing program was developed and implemented in a labor and delivery suite at an inner-city teaching hospital in a nonresearch setting. Between April 2002 and June 2005, 259 rapid HIV tests were performed. For the first 19 months of the study, the expedited enzyme-linked immunosorbent assay (ELISA) was performed in 62 patients. For the remainder of the study, the OraQuick rapid HIV-1 antibody test was performed in 197 patients. Turnaround times for the ELISA and OraQuick test were 262 minutes and 143 minutes, respectively, a significant difference (P = .002). Four women had positive test results. Voluntary rapid HIV testing is a feasible strategy for detection of HIV seropositivity in pregnant patients who present in a labor and delivery suite with unknown serostatus. This provides an opportunity to administer antiretroviral prophylaxis and to incorporate other obstetric interventions to decrease vertical HIV transmission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433470

Source DB:  PubMed          Journal:  AIDS Read        ISSN: 1053-0894


  2 in total

Review 1.  Rapid HIV testing: a review of the literature and implications for the clinician.

Authors:  Carlos Franco-Paredes; Ildefonso Tellez; Carlos del Rio
Journal:  Curr HIV/AIDS Rep       Date:  2006-11       Impact factor: 5.071

2.  Evaluation of diagnostic accuracy, feasibility and client preference for rapid oral fluid-based diagnosis of HIV infection in rural India.

Authors:  Nitika Pant Pai; Rajnish Joshi; Sandeep Dogra; Bharati Taksande; S P Kalantri; Madhukar Pai; Pratibha Narang; Jacqueline P Tulsky; Arthur L Reingold
Journal:  PLoS One       Date:  2007-04-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.